Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros

País/Región como asunto
Intervalo de año de publicación
2.
BMC Infect Dis ; 13: 60, 2013 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-23374914

RESUMEN

BACKGROUND: Hepatitis C chronic liver disease is a major cause of liver transplant in developed countries. This article reports the first nationwide population-based survey conducted to estimate the seroprevalence of HCV antibodies and associated risk factors in the urban population of Brazil. METHODS: The cross sectional study was conducted in all Brazilian macro-regions from 2005 to 2009, as a stratified multistage cluster sample of 19,503 inhabitants aged between 10 and 69 years, representing individuals living in all 26 State capitals and the Federal District. Hepatitis C antibodies were detected by a third-generation enzyme immunoassay. Seropositive individuals were retested by Polymerase Chain Reaction and genotyped. Adjusted prevalence was estimated by macro-regions. Potential risk factors associated with HCV infection were assessed by calculating the crude and adjusted odds ratios, 95% confidence intervals (95% CI) and p values. Population attributable risk was estimated for multiple factors using a case-control approach. RESULTS: The overall weighted prevalence of hepatitis C antibodies was 1.38% (95% CI: 1.12%-1.64%). Prevalence of infection increased in older groups but was similar for both sexes. The multivariate model showed the following to be predictors of HCV infection: age, injected drug use (OR = 6.65), sniffed drug use (OR = 2.59), hospitalization (OR = 1.90), groups socially deprived by the lack of sewage disposal (OR = 2.53), and injection with glass syringe (OR = 1.52, with a borderline p value). The genotypes 1 (subtypes 1a, 1b), 2b and 3a were identified. The estimated population attributable risk for the ensemble of risk factors was 40%. Approximately 1.3 million individuals would be expected to be anti-HCV-positive in the country. CONCLUSIONS: The large estimated absolute numbers of infected individuals reveals the burden of the disease in the near future, giving rise to costs for the health care system and society at large. The known risk factors explain less than 50% of the infected cases, limiting the prevention strategies. Our findings regarding risk behaviors associated with HCV infection showed that there is still room for improving strategies for reducing transmission among drug users and nosocomial infection, as well as a need for specific prevention and control strategies targeting individuals living in poverty.


Asunto(s)
Hepacivirus , Hepatitis C/epidemiología , Adolescente , Adulto , Anciano , Brasil/epidemiología , Niño , Estudios Transversales , Femenino , Genotipo , Hepacivirus/genética , Hepacivirus/inmunología , Hepatitis C/historia , Anticuerpos contra la Hepatitis C/sangre , Anticuerpos contra la Hepatitis C/inmunología , Historia del Siglo XXI , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Prevalencia , Factores de Riesgo , Población Urbana , Adulto Joven
3.
Mem Inst Oswaldo Cruz ; 105(1): 103-6, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20209338

RESUMEN

Given the scarcity of epidemiological information on hepatitis C virus (HCV) infection in Northern Brazil, we determined the prevalence and genotypic frequency in blood donors in the state of Pará (PA). Blood samples from all of the blood donors at the Fundação HEMOPA (blood bank of PA) from 2004-2006 were screened for the presence of antibodies to anti-HCV and samples seroreactive to anti-HCV were further tested for HCV RNA using real-time PCR. In total, 116 HCV-RNA samples were genotyped, based on maximum likelihood phylogenetic analyses, using BioEdit, Modelgenerator, PHYML and FigTree software. The population consisted of 242,726 volunteers who donated blood from 2004-2006; the most common subgroup was males between the ages of 18-29 years old (37.30%). Within the whole group, 1,112 blood donors (0.46%) had indeterminate or positive serology; among these, 28.78% were males whose ages ranged from 18-29 years. A diagnosis of chronic HCV infection was confirmed for 304 donors (60.20% males; 66.45% were 30-49 years old), resulting in a prevalence of HCV RNA in 0.13% of the samples (304 of 242,726). HCV genotyping revealed a high frequency of genotype 1 (108/116) followed by genotype 3 (8/116). This study found HCV infection to be relatively infrequent in PA; genotype 1 was most commonly isolated. This information can help guide prevention and control policies aimed at efficient diagnosis and control measures.


Asunto(s)
Donantes de Sangre , Hepacivirus , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/epidemiología , Adulto , Brasil/epidemiología , Femenino , Genotipo , Hepacivirus/genética , Hepacivirus/inmunología , Hepatitis C/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Prevalencia , ARN Viral/sangre , Adulto Joven
4.
Am J Trop Med Hyg ; 93(6): 1341-1348, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26503280

RESUMEN

A population-based hepatitis survey was carried out to estimate the prevalence of hepatitis B virus (HBV) infection and its predictive factors for the state capitals from the north, south, and southeast regions of Brazil. A multistage cluster sampling was used to select, successively, census tracts, blocks, households, and residents in the age group 10-69 years in each state capital. The prevalence of hepatitis B surface antigen (HBsAg) was lower than 1% in the north, southeast, and south regions. Socioeconomic condition was associated with HBV infection in north and south regions. Variables related to the blood route transmission were associated with HBV infection only in the south whereas those related to sexual behavior were associated with HBV infection in the north and south regions. Drug use was associated in all regions, but the type of drug differed. The findings presented herein highlight the diversity of the potential transmission routes for hepatitis B transmission in Brazil. In one hand, it reinforces the importance of national control strategies of large impact already in course (immunization of infants, adolescents, and adults up to 49 years of age and blood supply screening). On the other hand, it shows that there is still room for further control measures targeted to different groups within each region.


Asunto(s)
Vacunas contra Hepatitis B/uso terapéutico , Hepatitis B/epidemiología , Adolescente , Adulto , Factores de Edad , Anciano , Brasil/epidemiología , Niño , Femenino , Encuestas Epidemiológicas , Hepatitis B/etiología , Hepatitis B/prevención & control , Hepatitis B/transmisión , Antígenos de Superficie de la Hepatitis B/sangre , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Enfermedades Virales de Transmisión Sexual/epidemiología , Factores Socioeconómicos , Abuso de Sustancias por Vía Intravenosa/complicaciones , Adulto Joven
5.
Braz J Infect Dis ; 17(2): 194-204, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23490868

RESUMEN

The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (genotype 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the development of the direct-acting antiviral agents boceprevir and telaprevir with substantial increase in the rates of sustained virological response with shorter duration of therapy for a large number of patients. However, the complexity of triple therapy is higher and several new side effects are expected suggesting greater expertise in the patient management. Anemia and disgeusia are frequent with boceprevir while cutaneous rash, ranging from mild to severe, is expected with telaprevir. Higher risk of drug-drug interactions demand further clinical consideration of the previous well-known adverse events of pegylated interferon and ribavirin. Identification and prompt management of these potential new problems with boceprevir and telaprevir are crucial in clinical practice for optimizing treatment and assuring safety outcomes to HCV-genotype 1 patients.


Asunto(s)
Antivirales/efectos adversos , Hepatitis C Crónica/tratamiento farmacológico , Oligopéptidos/efectos adversos , Prolina/análogos & derivados , Inhibidores de Proteasas/efectos adversos , Interacciones Farmacológicas , Quimioterapia Combinada , Genotipo , Hepacivirus/genética , Humanos , Prolina/efectos adversos
6.
Rev Soc Bras Med Trop ; 44(1): 8-12, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21340399

RESUMEN

INTRODUCTION: Epidemiological studies concerning HCV genotypic distribution in the Brazilian Amazon are scarce. Thus, this study determined the patterns of distribution of HCV genotypes among different exposure categories in the State of Pará, Brazilian Amazon. METHODS: A cross-sectional study was conducted on 312 HCV-infected individuals belonging to different categories of exposure, who were attended at the HEMOPA, CENPREN and a private hemodialysis clinic in Belém. They were tested for HCV antibodies using an immunoenzymatic test, RNA-HCV, using real-time PCR and HCV genotyping through phylogenetic analysis of the 5' UTR. The population groups were epidemiologically characterized according to data collected in a brief interview or medical consultation. RESULTS: Genotype 1 predominated in all the different categories of HCV exposure. HCV genotypic distribution among blood donors comprised genotypes 1 (94%) and 3 (6%). All patients with chronic hematologic diseases had HCV genotype 1. The genotypic distribution in illicit-drug users comprised genotypes 1 (59.6%) and 3 (40.4%). In patients under hemodialysis, genotypes 1 (90.1%), 2 (3.3%), and 3 (6.6%) were detected. Finally, the frequency of genotypes 1 and 3 was significantly different between the groups: BD and DU, PUH and DU, PUH and PCHD and PCHD and DU. CONCLUSIONS: The genotypic frequency and distribution of HCV in different categories of exposure in the State of Pará showed a predominance of genotype 1, regardless of the possible risk of infection.


Asunto(s)
Regiones no Traducidas 5'/genética , Hepacivirus/genética , Hepacivirus/inmunología , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/virología , ARN Viral/sangre , Adulto , Brasil/epidemiología , Estudios Transversales , Femenino , Genotipo , Hepatitis C/epidemiología , Hepatitis C/transmisión , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa
7.
Cad Saude Publica ; 26(4): 837-44, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20512223

RESUMEN

We determined the risk factors for HCV infection in blood donors in the State of Pará, Northern Brazil. We examined 256 blood donors seen at the Blood Bank of Pará State between 2004 and 2006. They were divided into two groups, depending on whether they were infected with HCV or not; 116 donors were infected with HCV, while the other 140 were free of infection. The HCV-RNA was detected by real-time PCR. All of the participants filled out a questionnaire about possible risk factors. The data were evaluated using simple and multiple logistic regressions. The main risk factors for HCV were found to be use of needles and syringes sterilized at home (OR = 4.55), invasive dental treatment (OR = 3.08), shared use of razors at home (OR = 1.99), sharing of disposable razors in barbershops, beauty salons, etc. (OR = 2.34), and sharing manicure and pedicure material (OR = 3.45). Local and regional health authorities should educate the public about sharing perforating and cutting materials at home, in barber/beauty shops, and in dental clinics as risk factors for HCV infection.


Asunto(s)
Donantes de Sangre/estadística & datos numéricos , Hepacivirus/genética , Hepatitis C/transmisión , ARN Viral/sangre , Adulto , Brasil/epidemiología , Estudios de Casos y Controles , Femenino , Hepatitis C/diagnóstico , Hepatitis C/epidemiología , Humanos , Masculino , Reacción en Cadena de la Polimerasa , Factores de Riesgo , Encuestas y Cuestionarios
8.
Braz. j. infect. dis ; 17(2): 194-204, Mar.-Apr. 2013. ilus, tab
Artículo en Inglés | LILACS | ID: lil-673199

RESUMEN

The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (geno 3 type 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the development of the direct-acting antiviral agents boceprevir and telaprevir with substantial increase in the rates of sustained virological response with shorter duration of therapy for a large number of patients. However, the complexity of triple therapy is higher and several new side effects are expected suggesting greater expertise in the patient management. Anemia and disgeusia are frequent with boceprevir while cutaneous rash, ranging from mild to severe, is expected with telaprevir. Higher risk of drug-drug interactions demand further clinical consideration of the previous well-known adverse events of pegylated interferon and ribavirin. Identification and prompt management of these potential new problems with boceprevir and telaprevir are crucial in clinical practice for optimizing treatment and assuring safety outcomes to HCV-genotype 1 patients.


Asunto(s)
Humanos , Antivirales/efectos adversos , Hepatitis C Crónica/tratamiento farmacológico , Oligopéptidos/efectos adversos , Prolina/análogos & derivados , Inhibidores de Proteasas/efectos adversos , Interacciones Farmacológicas , Quimioterapia Combinada , Genotipo , Hepacivirus/genética , Prolina/efectos adversos
9.
Rev. Soc. Bras. Med. Trop ; 44(1): 8-12, Jan.-Feb. 2011. ilus, tab
Artículo en Inglés | LILACS | ID: lil-579822

RESUMEN

INTRODUCTION: Epidemiological studies concerning HCV genotypic distribution in the Brazilian Amazon are scarce. Thus, this study determined the patterns of distribution of HCV genotypes among different exposure categories in the State of Pará, Brazilian Amazon. METHODS: A cross-sectional study was conducted on 312 HCV-infected individuals belonging to different categories of exposure, who were attended at the HEMOPA, CENPREN and a private hemodialysis clinic in Belém. They were tested for HCV antibodies using an immunoenzymatic test, RNA-HCV, using real-time PCR and HCV genotyping through phylogenetic analysis of the 5' UTR. The population groups were epidemiologically characterized according to data collected in a brief interview or medical consultation. RESULTS: Genotype 1 predominated in all the different categories of HCV exposure. HCV genotypic distribution among blood donors comprised genotypes 1 (94 percent) and 3 (6 percent). All patients with chronic hematologic diseases had HCV genotype 1. The genotypic distribution in illicit-drug users comprised genotypes 1 (59.6 percent) and 3 (40.4 percent). In patients under hemodialysis, genotypes 1 (90.1 percent), 2 (3.3 percent), and 3 (6.6 percent) were detected. Finally, the frequency of genotypes 1 and 3 was significantly different between the groups: BD and DU, PUH and DU, PUH and PCHD and PCHD and DU. CONCLUSIONS: The genotypic frequency and distribution of HCV in different categories of exposure in the State of Pará showed a predominance of genotype 1, regardless of the possible risk of infection.


INTRODUÇÃO: Estudos epidemiológicos sobre a distribuição genotípica do HCV na Amazônia Brasileira são escassos. Baseado nisto, determinamos o padrão de distribuição genotípica do HCV em diferentes categorias de exposição no Estado do Pará, Amazônia Brasileira. MÉTODOS: Estudo transversal foi realizado com 312 indivíduos infectados pelo HCV, pertencentes a diferentes categorias de exposição atendidas pelo HEMOPA, CENPREN e uma clínica privada de hemodiálise em Belém. Eles foram testados quanto à presença de anticorpos anti-HCV por teste imunoenzimático, RNA-HCV utilizando PCR em tempo real e genotipados através de análise filogenética da 5' UTR. Os grupos de populações foram caracterizados epidemiologicamente de acordo com dados coletados em breve entrevista ou consulta de prontuários médicos. RESULTADOS: Em todas as diferentes categorias de exposição ao HCV, foram encontrados predomínio do genótipo 1. A distribuição genotípica do HCV em doadores de sangue (BD) foi constituída pelos genótipos 1 (94 por cento) e 3 (6 por cento). Todos os pacientes com doenças hematológicas crônicas (PCHD) possuíam genótipo 1. A distribuição genotípica em usuários de drogas ilícitas (DU) foi constituída pelos genótipos 1 (59,6 por cento) e 3 (40,4 por cento). Em pacientes em hemodiálise (PUH) foram detectados os genótipos 1 (90,1 por cento), 2 (3,3 por cento) e 3 (6,6 por cento). Finalmente, a frequência entre os genótipos 1 e 3 foi significativamente diferente entre os grupos: BD e DU, PUH e DU, PUH e PCHD, e PCHD e DU. CONCLUSÕES: A frequência genotípica e distribuição de HCV em diferentes categorias de exposição no Estado do Pará mostraram predominância do genótipo 1, independentemente do possível risco de infecção.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , /genética , Hepacivirus/genética , Hepacivirus/inmunología , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/virología , ARN Viral/sangre , Brasil/epidemiología , Estudios Transversales , Genotipo , Hepatitis C/epidemiología , Hepatitis C/transmisión , Reacción en Cadena de la Polimerasa
10.
Mem. Inst. Oswaldo Cruz ; 105(1): 103-106, Feb. 2010. tab, ilus
Artículo en Inglés | LILACS | ID: lil-539303

RESUMEN

Given the scarcity of epidemiological information on hepatitis C virus (HCV) infection in Northern Brazil, we determined the prevalence and genotypic frequency in blood donors in the state of Pará (PA). Blood samples from all of the blood donors at the Fundação HEMOPA (blood bank of PA) from 2004-2006 were screened for the presence of antibodies to anti-HCV and samples seroreactive to anti-HCV were further tested for HCV RNA using real-time PCR. In total, 116 HCV-RNA samples were genotyped, based on maximum likelihood phylogenetic analyses, using BioEdit, Modelgenerator, PHYML and FigTree software. The population consisted of 242,726 volunteers who donated blood from 2004-2006; the most common subgroup was males between the ages of 18-29 years old (37.30 percent). Within the whole group, 1,112 blood donors (0.46 percent) had indeterminate or positive serology; among these, 28.78 percent were males whose ages ranged from 18-29 years. A diagnosis of chronic HCV infection was confirmed for 304 donors (60.20 percent males; 66.45 percent were 30-49 years old), resulting in a prevalence of HCV RNA in 0.13 percent of the samples (304 of 242,726). HCV genotyping revealed a high frequency of genotype 1 (108/116) followed by genotype 3 (8/116). This study found HCV infection to be relatively infrequent in PA; genotype 1 was most commonly isolated. This information can help guide prevention and control policies aimed at efficient diagnosis and control measures.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Donantes de Sangre , Hepacivirus , Anticuerpos contra la Hepatitis C/sangre , Hepatitis C/epidemiología , Brasil/epidemiología , Genotipo , Hepacivirus/genética , Hepacivirus/inmunología , Hepatitis C/diagnóstico , Reacción en Cadena de la Polimerasa , Prevalencia , ARN Viral/sangre , Adulto Joven
11.
Cad. saúde pública ; 26(4): 837-844, abr. 2010. tab
Artículo en Inglés | LILACS | ID: lil-547219

RESUMEN

We determined the risk factors for HCV infection in blood donors in the State of Pará, Northern Brazil. We examined 256 blood donors seen at the Blood Bank of Pará State between 2004 and 2006. They were divided into two groups, depending on whether they were infected with HCV or not; 116 donors were infected with HCV, while the other 140 were free of infection. The HCV-RNA was detected by real-time PCR. All of the participants filled out a questionnaire about possible risk factors. The data were evaluated using simple and multiple logistic regressions. The main risk factors for HCV were found to be use of needles and syringes sterilized at home (OR = 4.55), invasive dental treatment (OR = 3.08), shared use of razors at home (OR = 1.99), sharing of disposable razors in barbershops, beauty salons, etc. (OR = 2.34), and sharing manicure and pedicure material (OR = 3.45). Local and regional health authorities should educate the public about sharing perforating and cutting materials at home, in barber/beauty shops, and in dental clinics as risk factors for HCV infection.


Nós determinamos os fatores de risco à infecção pelo HCV em doadores de sangue no Estado do Pará, Brasil. Foram analisados 256 doadores de sangue atendidos na Fundação HEMOPA de 2004 a 2006, sendo divididos em dois grupos: infectados e não-infectados. O diagnóstico foi realizado por PCR em tempo real. Todos os participantes responderam a questionário sobre possíveis fatores de risco, sendo a modelagem estatística feita por regressão logística simples e múltipla. Os fatores de risco à infecção foram: uso de agulhas e seringas de vidros esterilizadas em casa (OR = 4,55), realização de tratamento dentário invasivo (OR = 3,08), compartilhamento de lâminas em domicílio (OR = 1,99), compartilhamento de lâminas descartáveis em barbearias, salões de beleza (OR = 2,34), e compartilhamento de material de manicure e pedicure (OR = 3,45). As autoridades de saúde devem conscientizar a população sobre o compartilhamento de materiais perfuro-cortantes em domicílio, salões de beleza e consultórios dentários como fatores de risco à infecção.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Donantes de Sangre/estadística & datos numéricos , Hepacivirus/genética , Hepatitis C/transmisión , ARN Viral/sangre , Brasil/epidemiología , Estudios de Casos y Controles , Hepatitis C/diagnóstico , Hepatitis C/epidemiología , Reacción en Cadena de la Polimerasa , Factores de Riesgo , Encuestas y Cuestionarios
12.
Gastroenterology ; 127(5 Suppl 1): S97-103, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15508109

RESUMEN

Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma. Similar studies further indicate that diabetes is also a major risk factor. Both obesity and diabetes are frequently associated with nonalcoholic fatty liver disease, and case reports have shown progression of nonalcoholic fatty liver disease to cirrhosis and hepatocellular carcinoma. Although no study has clearly tied all of these variables together, it is likely that the association of hepatocellular carcinoma with obesity represents the progression of underlying nonalcoholic fatty liver disease to cirrhosis. The mechanism most likely involves replicative senescence of steatotic mature hepatocytes and compensatory hyperplasia of progenitor (oval) cells as a reaction to chronic injury due to ongoing nonalcoholic steatohepatitis and resultant hepatic fibrosis. Growth factors associated with chronic inflammation, type 2 diabetes, and DNA mutations as a result of lipid peroxidation probably play significant roles in clonal expansion and hepatocellular carcinoma progression. It remains unclear whether cirrhosis is a prerequisite for the development of hepatocellular carcinoma or whether hepatocellular carcinoma can develop in fatty liver in the absence of cirrhosis. However, well-documented case reports suggest that most cases of hepatocellular carcinoma arise in the setting of nonalcoholic steatohepatitis with cirrhosis. Whether therapy aimed at nonalcoholic fatty liver disease reduces the risk of hepatocellular carcinoma remains to be shown. Prophylactic measures and the role of cancer surveillance have not been adequately investigated, but current evidence suggests a risk for hepatocellular carcinoma in nonalcoholic steatohepatitis-related cirrhosis that rivals that of hepatocellular carcinoma in hepatitis C virus-related cirrhosis, particularly in older male patients.


Asunto(s)
Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/fisiopatología , Hígado Graso/complicaciones , Neoplasias Hepáticas/etiología , Neoplasias Hepáticas/fisiopatología , Obesidad/complicaciones , Adulto , Factores de Edad , Anciano , Carcinoma Hepatocelular/epidemiología , Transformación Celular Neoplásica , Daño del ADN , Complicaciones de la Diabetes , Femenino , Sustancias de Crecimiento , Hepatitis C/complicaciones , Humanos , Inflamación , Neoplasias Hepáticas/epidemiología , Masculino , Persona de Mediana Edad , Factores de Riesgo , Factores Sexuales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA